ABSTRACT BS-513: Sodium Channel Related Arrhythmias

Friday, April 29, 2022
2:15 PM - 3:15 PM

BS-513-01

SUPPRESSION-REPLACEMENT GENE THERAPY FOR SCN5A-MEDIATED TYPE 3 LONG QT SYNDROME

Martina Gluscevic PhD, MS; Changsung John Kim PhD; David Tester BS; Maengjo Kim PhD; Sahej Bains BS and Michael John Ackerman MD, PhD

Background: Congenital long QT syndrome (LQTS) is an autosomal dominant disorder characterized by delayed repolarization of the myocardium with a prolonged QT interval on electrocardiogram that may manifest as syncope, seizure, or sudden cardiac arrest/death. Long QT syndrome type 3 (LQT3) is caused by gain-of-function mutations in the SCN5A-encoded Na,1.5 sodium channel. No current therapies target the molecular cause of LQT3.

Objective: To develop an SCN5A suppression-replacement (SupRep) gene therapy to rescue the prolonged cardiac action potential duration (APD) in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from a patient with LQT3.

Methods: Custom designed shRNAs targeting SCN5A were tested for knockdown efficiency using TSA201 cells and RT-qPCR. A dual-component “suppression-and-replacement” (SupRep) SCN5A gene therapy was created by cloning into a single construct a custom-designed SCN5A shRNA that produces ~90% knockdown (suppression) and a “shRNA-immune” (shIMM) SCN5A cDNA (replacement). Patient-specific SCN5A-F1760C iPSC-CMs were generated form a patient with severe LQT3 (QTc > 680ms). FluoVolt voltage dye was used to measure the APD at 90% repolarization (APD90).

Results: Six unique shRNAs targeting SCN5A were tested, and one candidate shRNA was identified that suppressed the endogenous SCN5A alleles in TSA201 cells with about 92% knockdown efficiency. Compared to control iPSC-CMs, the baseline APD90 was significantly prolonged in SCN5A-F1760C iPSC-CM cells [680 ± 20 ms (n=30) vs 342 ± 16 ms (n=20), p<0.0001]. Following treatment with SCN5A-SupRep gene therapy, the APD90 was significantly decreased in F1760C iPSC-CMs compared to untreated cells [F1760C: 680 ± 20 ms (n=30) vs F1760C + SupRep: 470 ± 18 ms (n=39), p<0.0001]. This strategy demonstrated that the SCN5A-SupRep gene-therapy can rescue the pathologically prolonged APD in LQT3 patient-derived iPSC-CMs.

Conclusion: We provide the first proof-of-principle gene therapy for correction of LQT3. Akin to our sentinel discovery of SupRep gene therapy for LQT1, SCN5A-SupRep gene therapy successfully corrected/normalized the pathologic APD90, thereby eliminating the pathognomonic feature of LQT3.

BS-513-02

GENOME-WIDE ASSOCIATION ANALYSES IDENTIFY NOVEL BRUGADA SYNDROME RISK LOCI AND HIGHLIGHT A NEW MECHANISM OF SODIUM CHANNEL REGULATION IN DISEASE SUSCEPTIBILITY

Julien Barc PhD; Rafik Tadros MD, PhD; Charlotte Glinge; David Y. Chiang MD, PhD; Mariam Jouni PhD; Floriane Simonet; tium The International Brugada Syndrome Genetics Consor, Michael Tanck; Alfred L. George MD; Calum A. MacRae MD, PhD; Paul Burridge PhD; Christian Dina PhD; Vincent Probst MD; Arthur A.M. Wilde MD, PhD; Jean-Jacques Schott PhD; Richard Redon and Connie R. Bezzina PhD

Background: Brugada syndrome (BrS) is a cardiac arrhythmia disorder associated with sudden death in young adults. With the exception of SCN5A, encoding the cardiac sodium channel NaV1.5, susceptibility genes remain largely unknown.

Objective: Evaluate the contribution of the common variants in the genetic architecture of the BrS.

Methods: We performed a genome-wide association meta-analysis comprising 2,820 unrelated cases with BrS and 10,001 controls.

Results: We identified 21 association signals (18 novel) at 12 loci (10 novel). Seven association signals overlap SCN5A and one overlaps the neighboring SCN10A gene encoding the sodium channel isoform NaV1.8 highlighting the primacy of sodium channel function in BrS susceptibility. Notably, 10 association signals overlapped or are in the vicinity of 8 genes encoding cardiac developmental transcription factors (HEY2, TBX20, ZFPM2, GATA4, WT1, TBX5, IRX3 and IRX5) pointing to transcriptional regulation as a key feature of BrS pathogenesis.

Conclusion: Taken together, these findings broaden our understanding of the genetic architecture of Brugada syndrome and provide new insights into its molecular underpinnings.

BS-513-03

SCN5A MUTATIONS AND THE ROLE OF GENETIC BACKGROUND IN THE PATHOPHYSIOLOGY OF BRUGADA SYNDROME

Vincent Probst MD; Sylvie Geoffroy; Sylvie Geoffroy; Philippe MABO; Jacques Mansourati MD; Jean-Luc Pasquie MD, PhD; Sylvie Geoffroy MD; Alain Al Amaout MD; Dewey Pettit; Olivier Billon; Philippe MABO; Frederic Sacher MD, PhD and Jean Baptiste Gouraud MD, PhD

Background: Mutations in SCN5A are identified in approximately 20% to 30% of probands affected by Brugada syndrome (BrS). However, in familial studies, the relationship between SCN5A mutations and BrS remains poorly understood.

Objective: The aim of this study was to investigate the association of SCN5A mutations and BrS in a group of large genotyped families.

Methods: Families were included if at least 3 family members were carriers of the SCN5A mutation, which was identified in the proband. Families were recruited from 12 tertiary centers in France between 1995 and 2020. Type 1 ST elevation was defined by ≥2 mm J-point elevation with coved ST segment and negative T wave.

Results: Forty-nine large families composed of 600 members including 304 mutation carriers (51%) were studied. The
signature type I ECG was present in 160 mutation carriers (BrS-ECG+; 53%). In 42 families, we found 33 individuals affected by BrS but with a negative genotype (mutation-negative BrS-ECG+). Among them, 5 patients have an ECG suggestive of BrS but without the complete signature type I ECG. Among these 33 mutation-negative BrS-ECG+ individuals, 3 (9%), belonging to 3 different families, had a spontaneous type I ECG, whereas 28 had a type I ECG only after the administration of sodium channel blockers. Three of these 33 individuals (9%) had also experienced syncope. Mutation carriers had, on average, longer PR (190 ± 36 ms vs 154 ± 29 ms, p<0.0001) and QRS (107 ± 19 vs 92 ± 29 ms, p<0.0001) intervals than noncarriers, demonstrating that these mutations exerted functional effects.

**Conclusion:** Our results suggest that SCN5A mutations are not directly causal to the occurrence of a BrS-ECG+ and that genetic background may play a powerful role in the pathophysiology of BrS. These findings are consistent with the notion that the pathophysiology of BrS includes various elements beyond mutant sodium channels.

**BS-513-04**

**BURDEN AND CLINICAL CHARACTERISTICS OF THAI BRUGADA SYNDROME PATIENTS CARRYING RARE SCN5A VARIANTS OF UNCERTAIN SIGNIFICANCE**

John Mauleekoonphairoj MSc; Apichai Khongphatthanayothin; Roddy Walsh; Boosasam Sutjaporn; Pharawee Wandee; Arthur A.M. Wilde MD, PhD; Yong Poovorawan; Connie R. Bezzina PhD and Koonlawee Nademanee MD, FHRS, CCDs

**Background:** Loss-of-function variants in the sodium channel α-subunit (SCN5A) are associated with Brugada Syndrome (BrS). As Southeast Asians are understudied, the detected variants often lack supporting evidence and are absent in current clinical databases. This creates a challenge as variant interpretation resulted in over 90% of rare variants detected being classified as variants of uncertain significance (VUS) according to ACMG guideline.

**Objective:** To investigate the burden of rare SCN5A variants in Thai BrS patients and to examine the clinical characteristics of BrS patients with rare SCN5A variants.

**Methods:** Burden testing was performed on 196 cases and 394 controls. Rare variants, with allele frequency in gnomAD < 0.01, were included. Testing was further performed on variants prioritized with CADD score, a measure of variant deleteriousness (CADD≥25). Clinical characteristics of Brugada Syndrome patients with rare SCN5A variants were assessed.

**Results:** Rare SCN5A variants are associated with Thai BrS cases (p = 0.04, 8.16% vs 3.04%). An enrichment of prioritized variants was observed in BrS cases (p = 2.31x10−5, 5.61% vs 0.5%). No significant differences were found in clinical characteristics of patients with and without rare SCN5A variants. However, patients with prioritized SCN5A variants (n=11) showed significantly earlier age-onset of first cardiac event when compared to patients with rare SCN5A variants (p < 0.02, upper figure) and other BrS cases in the cohort (p < 0.01 lower figure).

**Conclusion:** BrS patients carrying SCN5A variants predicted to be deleterious show earlier age-onset of first cardiac event. The variable clinical characteristic in patients with rare SCN5A and prevalence of rare SCN5A variants in controls suggests that interpreting rare variants must be done with caution, especially in understudied populations where supporting evidence is limited. Further studies are needed for using prioritized SCN5A variants to aid in the diagnosis or prognostication of patients with BrS.

**ABSTRACT CA-530:**

**Delivering Durable Lesions: Utilizing Surrogates to Guide Ablation in the Atrium and Ventricle**

Friday, April 29, 2022

2:15 PM - 3:15 PM

**CA-530-01**

**USE THE FORCE: ADEQUATE CATHETER CONTACT FORCE IS CRITICAL FOR HIGH QUALITY LESIONS GUIDED BY ABLATION INDEX**

Omar Kreidieh MD; Clinton J. Thurber MD; John Whitaker BCH, BM, PhD; Nathaniel Steiger MD; Uyangna Batnyam MD; David Chang MD; Sunil Kapur MD; Thomas M. Tadros MD, MPH; Bruce A. Koplan MD, MPH, FHRS; Usha B. Tedrow MD, MS, FHRS; William H. Sauer MD, FHRS, CCDS and Paul C. Zei MD, PhD, FHRS

**Background:** Ablation Index (AI) is a measure used to estimate lesion size based on power, contact force (CF), and lesion duration. Ideally, AI-guided titration of lesion duration corrects for variations in contact force. Impedance drop is a validated measure that correlates well with lesion formation. Therefore, analysis of the relationship between AI, CF, and impedance drop may offer insight into possible residual influences of CF on lesion formation.

**Objective:** To investigate and characterize the impact of CF on impedance drop during AI-guided ablation.

**Methods:** We retrospectively reviewed atrial fibrillation ablation cases (AFAs) performed at a single center. We examined the correlation between CF and Impedance drop within narrow ranges of AI (17 groups). In a secondary analysis, we matched lesion pairs with high and low CF (< 10 g and > 20 g) for stability, AI, lesion location, and power. Matched pairs were compared using a t-test.

**Results:** There were 13444 lesions with AI between 320 and 530 from 91 AFAs. For lesions that had a low AI (< 402.3), we observed mostly no residual correlation between contact force and impedance drop (Fig 1). For lesions with high AI (> 402.3), we observed a consistent significant correlation between CF and impedance drop (Fig 1).

In the matched sample, the high CF group had a greater impedance drop when compared to the low CF group: 8.5 ± 5.3 vs 7.0 ± 4.0 Ohms p < 0.01 (Figure 2), despite having similar AI. When examining the subset of matched pairs with AI < 400, we observed no significant difference in impedance drop between the high and low CF groups: 6.7 ± 4.7 vs 6.5 ± 4.1 Ohms (p = 0.6). When examining the matched pairs with AI > 400, we again